Arvinas is a biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade disease-causing proteins. Co. is developing ARV-110, a proteolysis targeting chimeras (PROTAC) targeted protein degrader targeting the androgen receptor protein for the treatment of men with metastatic castration-resistant prostate cancer. Co. is also developing ARV-471, a PROTAC targeted protein degrader targeting the estrogen receptor protein, or ER, for the treatment of patients with locally advanced or metastatic ER positive / HER2 negative breast cancer. The ARVN stock yearly return is shown above.
The yearly return on the ARVN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ARVN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|